Clinical trials: Progesterone
Brain Injuries
Efficacy and Safety Study of Intravenous Progesterone in Patients With Severe Traumatic Brain Injury
The SyNAPSe trial will study if giving intravenous (i.v.) progesterone within 8 hours of the injury for a total of 120 hours to severe traumatic brain injury patients improves their recovery.
- Trial name
- SyNAPSe (NCT01143064)
- Testing
- Progesterone, Lipid emulsion without progesterone
- Where
- 156 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- BHR Pharma, LLC
Infertility
Efficacy and Safety of Crinone Versus Combination Medication (ACCESS)
The study to compare to the efficacy and safety of Crinone versus combination medication in infertile women receive frozen-thawed embryo transfer (FET) in artificial cycles (AC).
- Trial name
- NCT03858049
- Testing
- Crinone, Duphaston
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Menopause
A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.
- Trial name
- REPLENISH (NCT01942668)
- Testing
- Estradiol, Progesterone
- Where
- 119 sites in United States
- Volunteers
- 1,845 people
- Sponsor
- TherapeuticsMD
Luteal Phase Defect
Progesterone in Luteal Phase Deficiency
The main objective of this study will be to assess the efficacy of natural progesterone at a daily dose of 25 mg in restoring a normal luteal phase. The primary end-point will be the ongoing pregnancy rate.
- Trial name
- NCT02950948
- Testing
- Progesterone
- Sponsor
- IBSA Institut Biochimique SA
Secondary Amenorrhea
Safety and Efficacy of PROMETRIUM® Capsules in Induction of Secretory Conversion
To evaluate the efficacy and safety of 300 mg and 400 mg doses of PROMETRIUM® capsules in women of reproductive age with secondary amenorrhea
- Trial name
- NCT00160199
- Testing
- PROMETRIUM® 300 mg, PROMETRIUM® 400 mg
- Where
- 42 sites in United States
- Volunteers
- 240 people
- Sponsor
- Solvay Pharmaceuticals
Her2 Negative Breast Cancer Patients
Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer
To determine whether the combination MM-121 + Exemestane in ER+ and/or PR+ breast cancer patients is more effective than Exemestane alone
- Trial name
- NCT01151046
- Testing
- MM-121, Exemestane
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 118 people
- Sponsor
- Merrimack Pharmaceuticals
Preterm Birth
17OHP for Reduction of Neonatal Morbidity Due to Preterm Birth (PTB) in Twin and Triplet Pregnancies
Hypothesis: Among women with twin or triplet pregnancies, weekly injections of 17-alpha-hydroxyprogesterone caproate (17OHP), started before 24 weeks of gestation, will reduce neonatal morbidity by reducing the rate of preterm…
- Trial name
- 170HP (NCT00163020)
- Testing
- 17-alpha-hydroxyprogesterone caproate injectable
- Where
- 18 sites in United States
- Volunteers
- 321 people
- Sponsor
- Obstetrix Medical Group
Preterm Delivery, Short Cervix
PREGNANT Short Cervix Trial
The purpose of this research study is to evaluate the usefulness of progesterone vaginal gel in decreasing the preterm birth rate in a population of pregnant women with short cervical length and at high risk for preterm birth.
- Conditions
- Preterm Delivery, Short Cervix, Short Uterine Cervical Length
- Trial name
- NCT00615550
- Testing
- progesterone
- Where
- 49 sites in United States, Belarus and 8 more
- Volunteers
- 465 people, healthy volunteers welcome
- Sponsor
- Juniper Pharmaceuticals, Inc.
Breast Cancer
Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer
This study is being carried out to see if treatment with ZD1839 (Gefitinib) combined with Arimidex (Anastrozole) has improved efficacy over Arimidex alone in preventing progression of metastatic breast cancer.
- Trial name
- NCT00077025
- Testing
- Gefitinib, Anastrozole
- Where
- 27 sites in United States, Colombia and 2 more
- Volunteers
- 174 people
- Sponsor
- AstraZeneca
Pharmacokinetics
Characterization of the Pharmacokinetics of a Vaginal Ring With 2.0 g Progesterone in Post-menopausal Women
This is a single site, open-label, randomized, single-dose, Phase 1 study in post-menopausal women.
- Trial name
- NCT03737656
- Testing
- Progesterone vaginal ring
- Where
- Mexico
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Preterm Birth
Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery
Assess the efficacy of 2 Cervical Pessaries containing 6.3 g and 7.7 g micronized progesterone for the prevention of preterm delivery, established through spontaneous birth before gestation weeks 32 (31 weeks and 6 days) and 34…
- Trial name
- PCP002 (NCT02225353)
- Testing
- Progesterone Cervical Pessary 6.3 g, Progesterone 200 mg vaginal capsules, Progesterone Cervical Pessary 7.7 g
- Where
- 4 sites in Chile
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Infertility
Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)
This study is aimed to demonstrate that highly purified Menotrophin produces significant lower progesterone serum levels during the follicular phase in comparison to Follitropin alpha in the treatment of subfertile females…
- Trial name
- PREDICT (NCT01225835)
- Testing
- Menotrophin, Follitrophin alpha, Cetrorelix
- Where
- 8 sites in Germany
- Volunteers
- 124 people
- Sponsor
- Ferring Pharmaceuticals
Endometriosis
Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study
ZPE-201 Extension of treatment
- Trial name
- NCT00958412
- Testing
- Proellex®
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Repros Therapeutics Inc.
Uterine Fibroids, Anemia
Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids
Eligible female subjects will be randomly assigned to one of the three treatment groups. Subjects will receive 325 mg (65 mg elemental iron) iron supplements to be taken twice daily during study drug treatment.
- Trial name
- NCT00702702
- Testing
- Proellex 25 mg, Proellex 50 mg
- Where
- 30 sites in United States
- Volunteers
- 56 people
- Sponsor
- Repros Therapeutics Inc.
Breast Cancer
Re-Examination of Tumor Material and Re-Evaluation of Patient Data From Patients Treated With Neo-adjuvant Therapy
This is a prospective examination of ribonucleic acid (RNA) extracted from tumor material of breast cancer patients treated with a neo-adjuvant therapy.
- Trial name
- NCT02449993
- Testing
- MammaTyper™
- Volunteers
- 101 people
- Sponsor
- BioNTech Diagnostics GmbH
Threatened Miscarriage
Non-interventional Study of Therapy for Threatened Miscarriage
Study the efficacy and safety of therapy for threatened miscarriage with medicinal products Utrogestan (micronized progesterone), 200 mg capsules (Besins Healthcare SA, Belgium), and Duphaston (Dydrogesterone), 10 mg coated…
- Trial name
- NCT03309735
- Testing
- Micronized progesterone, Dydrogesterone
- Where
- 17 sites in Russia
- Volunteers
- 1,241 people
- Sponsor
- Besins Healthcare
Mental Health Wellness 1, Preterm Birth
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
This randomized controlled trial will test an intervention called the Mastery Lifestyle Intervention (the MLI) that was developed from data of 1000+pregnant Hispanic women related to risks of preterm birth.
- Trial name
- MLI (NCT05012072)
- Testing
- The Mastery Lifestyle Intervention
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- Microgen LLC
Progesterone Supplementation in Women Undergoing ART
Clinical Safety Study of the Progesterone Vaginal Ring in Women Undergoing Assisted Reproductive Technology Procedures
The purpose of the study is to assess the safety of Progesterone Vaginal Ring (PVR) in women undergoing fresh embryo transfer (ART).
- Trial name
- SARA (NCT03565211)
- Testing
- Progesterone vaginal ring
- Where
- 15 sites in United States
- Volunteers
- 352 people
- Sponsor
- Ferring Pharmaceuticals
Solid Tumor, Solid Tumor, Adult
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolerated dose (MTD) and/or preliminary recommended dose for expansion (RDE) of…
- Conditions
- Solid Tumor, Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Tumor
- Trial name
- NCT06264921
- Testing
- NKT3447
- Where
- 8 sites in United States
- Volunteers
- 23 people
- Sponsor
- NiKang Therapeutics, Inc.
Recurrent or Persistent Endometrial Carcinoma
Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA
This is an open label, multi-center, single arm phase II study. The study will investigate the efficacy of sodium cridanimod in conjunction with progestin therapy in a population of patients with recurrent or persistent…
- Trial name
- NCT02064725
- Testing
- Sodium cridanimod
- Where
- 21 sites in United States, Belarus and 3 more
- Volunteers
- 8 people
- Sponsor
- Kevelt AS